Our results are, as well, confirmed for the upregulation of the CA9 gene in the Non-Resp group, the inhibition of which enhances the sensitivity of glioma cells to TMZ treatment, and highlights the value of developing small molecules or antibodies against the CA9 pathway, for combination therapy with TMZ (31)(Supplementary Table 9; Figure 5A). This evidence concerns the gene CA9 and glioma.